Staffan Berg

Staffan Berg

Auto-generated profile, based on publicly available information

Staffan Berg

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
CRCarl Roos
Carl Roos
DDDavid Dahlgren
David Dahlgren
SBStaffan Berg
Staffan Berg
JWJan Westergren
Jan Westergren
BABertil Abrahamsson
Bertil Abrahamsson
HLHans Lennernäs
Hans Lennernäs

20 December 2021 in Molecular Pharmaceutics
Verified
Journal Article
Open access
SBStaffan Berg
Staffan Berg
LKLillevi Kärrberg
Lillevi Kärrberg
DSDenny Suljovic
Denny Suljovic
FSFrank Seeliger
Frank Seeliger
MSMagnus Söderberg
Magnus Söderberg
CBChristel BERGSTRÖM
Christel BERGSTRÖM
In this work, we set out to better understand how the permeation enhancer sodium caprate (C10) influences the intestinal absorption of macromolecules. FITC-dextran 4000 (FD4) was selected as a model compound and formulated with 50–300 mM C10. Absorption was studied after bolus instillation of liquid formulation to the duodenum of anesthetized rats and intravenously as a reference, whereafter plasma samples were taken and analyzed for FD4 content. It was found that the AUC and Cmax of FD4 increased with increasing C10 concentration. Higher C10 concentrations were associated with an increased and extended absorption but also increased epithelial damage. Depending on the C10 concentration, the intestinal epithelium showed significant recovery already at 60–120 min after administration. At the highest studied C10 concentrations (100 and 300 mM), the absorption of FD4 was not affected by the colloidal structures of C10, with similar absorption obtained when C10 was administered as micelles (pH 8.5) and as vesicles (pH 6.5). In contrast, the FD4 absorption was lower when C10 was administered at 50 mM formulated as micelles as compared to vesicles. Intestinal dilution of C10 and FD4 revealed a trend of decreasing FD4 absorption with increasing intestinal dilution. However, the effect was smaller than that of altering the total administered C10 dose. Absorption was similar when the formulations were prepared in simulated intestinal fluids containing mixed micelles of bile salts and phospholipids and in simple buffer solution. The findings in this study suggest that in order to optimally enhance the absorption of macromolecules, high (≥100 mM) initial intestinal C10 concentrations are likely needed and that both the concentration and total dose of C10 are important parameters.

1 June 2022 in Molecular Pharmaceutics
Verified
Journal Article
Open access
SBStaffan Berg
Staffan Berg
DSDenny Suljovic
Denny Suljovic
LKLillevi Kärrberg
Lillevi Kärrberg
MEMaria Englund
Maria Englund
HBHeiko Bönisch
Heiko Bönisch
CBChristel BERGSTRÖM
Christel BERGSTRÖM
In this work, we studied the intestinal absorption of a peptide with a molecular weight of 4353 Da (MEDI7219) and a protein having a molecular weight of 11 740 Da (PEP12210) in the rat intestinal instillation model and compared their absorption to fluorescein isothiocyanate (FITC)-labeled dextrans of similar molecular weights (4 and 10 kDa). To increase the absorption of the compounds, the permeation enhancer sodium caprate (C10) was included in the liquid formulations at concentrations of 50 and 300 mM. All studied compounds displayed an increased absorption rate and extent when delivered together with 50 mM C10 as compared to control formulations not containing C10. The time period during which the macromolecules maintained an increased permeability through the intestinal epithelium was approximately 20 min for all studied compounds at 50 mM C10. For the formulations containing 300 mM C10, it was noted that the dextrans displayed an increased absorption rate (compared to 50 mM C10), and their absorption continued for at least 60 min. The absorption rate of MEDI7219, on the other hand, was similar at both studied C10 concentrations, but the duration of absorption was extended at the higher enhancer concentration, leading to an increase in the overall extent of absorption. The absorption of PEP12210 was similar in terms of the rate and duration at both studied C10 concentrations. This is likely caused by the instability of this molecule in the intestinal lumen. The degradation decreases the luminal concentrations over time, which in turn limits absorption at time points beyond 20 min. The results from this study show that permeation enhancement effects cannot be extrapolated between different types of macromolecules. Furthermore, to maximize the absorption of a macromolecule delivered together with C10, prolonging the duration of absorption appears to be important. In addition, the macromolecule needs to be stable enough in the intestinal lumen to take advantage of the prolonged absorption time window enabled by the permeation enhancer.

1 August 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HRHanna A. Rydberg
Hanna A. Rydberg
MAMarianna Yanez Arteta
Marianna Yanez Arteta
SBStaffan Berg
Staffan Berg
LLLennart Lindfors
Lennart Lindfors
KSKalle Sigfridsson
Kalle Sigfridsson

28 September 2016 in Drugs
Verified
Journal Article
Open access
PDF file
MJMagnus Jörntén-Karlsson
Magnus Jörntén-Karlsson
SPStéphane Pintat
Stéphane Pintat
MMMichael Molloy-Bland
Michael Molloy-Bland
SBStaffan Berg
Staffan Berg
MAMatti Ahlqvist
Matti Ahlqvist
Poor adherence to statins increases cardiovascular disease risk. We systematically identified 32 controlled studies that assessed patient-centered interventions designed to improve statin adherence. The limited number of studies and variation in study characteristics precluded strict quality criteria or meta-analysis. Cognitive education or behavioural counselling delivered face-to-face multiple times consistently improved statin adherence compared with control groups (7/8 and 3/3 studies, respectively). None of four studies using medication reminders and/or adherence feedback alone reported significantly improved statin adherence. Single interventions that improved statin adherence but were not conducted face-to-face included cognitive education in the form of genetic test results (two studies) and cognitive education via a website (one study). Similar mean adherence measures were reported for 17 intervention arms and were thus compared in a sub-analysis: 8 showed significantly improved statin adherence, but effect sizes were modest (+7 to +22 % points). In three of these studies, statin adherence improved despite already being high in the control group (82–89 vs. 57–69 % in the other studies). These three studies were the only studies in this sub-analysis to include cognitive education delivered face-to-face multiple times (plus other interventions). In summary, the most consistently effective interventions for improving adherence to statins have modest effects and are resource-intensive. Research is needed to determine whether modern communications, particularly mobile health platforms (recently shown to improve medication adherence in other chronic diseases), can replicate or even enhance the successful elements of these interventions while using less time and fewer resources.

6 December 2023 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
PEProsper Emeh
Prosper Emeh
KBKatarina Breitholtz
Katarina Breitholtz
SBStaffan Berg
Staffan Berg
CVCharlotta Vedin
Charlotta Vedin
MEMaria Englund
Maria Englund
NDNigel Davies
Nigel Davies